Stent choice matters. A wealth of clinical evidence supports the safety of the XIENCE™ Stent, which is why experts consider XIENCE™ Stent to be the gold standard among DES.1
In addition, reproducible procedural outcomes are a proven quality of XIENCE™ DES performance,2 delivering consistent patient safety with low complication rates3
When choosing XIENCE™ Stent, interventional cardiologists (ICs) can know that the optimal outcomes they achieved in the cath lab will persist far into the future—not only treating stenosed vessels but enabling patients to have a better quality of life.3,4
Substantial clinical data continue to provide evidence that XIENCE™ DES can effectively treat a broad spectrum of patients.1 Given the excellent deliverability and the expanded treatment options of XIENCE Skypoint,7 it is an excellent choice for complex patients.
XIENCE™ Stent with 1-month or 3-month DAPT showed no increase in ischemic events with an observed reduction in bleeding in HBR patients.8
Note: PS stratified analysis for BARC 3-5 bleeding was not pre-specified.
Note: BARC 2-5 was a powered secondary endpoint.
NOTE: Antiplatelet drugs should be used in combination with the XIENCE stent, per the guidelines from the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions (ACC/AHA/SCAI). DAPT regimen is at the discretion of the physician and dependent on individual patient needs. Data from the short DAPT program, XIENCE 28, showed that 1-month DAPT (as short as 28 days) duration post-PCI is safe for HBR patients.
XIENCE™ Stent vs Synergy‡ with short-term safety outcomes in real-world patients.9
XIENCE™ Stent vs Resolute‡ Safety data from RAC real-world patients also reveal that XIENCE™ Stent outperforms Resolute.‡10
MAT-2113789 v1.0
INDICATIONS
Applies to XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems:
In addition, XIENCE Skypoint™ Stent System is indicated with reference vessel diameters of ≥ 2.25 mm to ≤ 5.25 mm.
CONTRAINDICATIONS
The XIENCE Skypoint™, XIENCE Sierra™ and XIENCE Alpine™ Stent Systems are contraindicated for use in:
WARNINGS
PRECAUTIONS
POTENTIAL ADVERSE EVENTS
Adverse events that may be associated with PCI treatment procedures and the use of a stent in native coronary arteries include, but are not limited to, the following:
The risks described below include the anticipated adverse events relevant for the cardiac population referenced in the contraindications, warnings and precaution sections of the everolimus labels / SmPCs and / or observed at incidences ≥ 10% in clinical trials with oral everolimus for different indications. Please refer to the drug SmPCs and labels for more detailed information and less frequent adverse events.
Applies only to XIENCE Sierra™ and XIENCE Alpine™
Live vaccines should be avoided and close contact with those that have had live vaccines should be avoided. Fetal harm can occur when administered to a pregnant woman. There may be other potential adverse events that are unforeseen at this time.
MAT-2100879 v5.0
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test